MENARINI Group, shared on LinkedIn:
“Menarini Group and Ryvu Therapeutics announce first clinical data from the Phase II JASPIS-01 study of dapolsertib (MEN1703, SEL24) in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma at the 2026 ASH annual meeting.
‘Patients with aggressive B-cell lymphoma whose disease progresses after CAR-T cell therapy and bispecific antibodies have limited treatment options and face very poor outcomes,’
said Elcin Barker Ergun, CEO of the Menarini Group.
‘The encouraging initial findings in heavily pretreated patients support the continued clinical development of dapolsertib, a first-in-class oral dual PIM/FLT3 inhibitor, as a potential option for this grim disease, and we look forward to further results from the ongoing study.’
Read today’s press release.”
Main achievements of Menarini Group.
- 140 years of pharmaceutical heritage: Established a long-standing international presence, developing expertise in pharmaceuticals, healthcare, and diagnostics.
- Expansion of oncology innovation: Strengthened its oncology pipeline through strategic partnerships, including collaborations to develop novel cancer therapies using artificial intelligence (AI)-discovered drug candidates.
- Broad therapeutic portfolio: Developed activities across multiple therapeutic areas, including oncology, cardiometabolic diseases, infectious diseases, respiratory conditions, gastrointestinal disorders, and dermatology.
- Global research and strategic partnerships: Built international collaborations and integrated research and development capabilities, supported by a global commercial presence and activities in pharmaceuticals, consumer healthcare, advanced diagnostics, and aesthetic medicine.
You may also be interested in:
Georgiamune Signs $1.1 Billion Global Licensing Deal With MENARINI Group – Parker Institute